1. AHRO : Austin Health Research Online
  2. Austin Health research
  3. Journal articles
Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16806
Full metadata record
DC FieldValueLanguage
dc.contributor.authorItchins, M-
dc.contributor.authorChia, Puey Ling-
dc.contributor.authorHayes, SA-
dc.contributor.authorHowell, VM-
dc.contributor.authorGill, AJ-
dc.contributor.authorCooper, WA-
dc.contributor.authorJohn, Thomas-
dc.contributor.authorMitchell, Paul L R-
dc.contributor.authorMillward, M-
dc.contributor.authorClarke, SJ-
dc.contributor.authorSolomon, B-
dc.contributor.authorPavlakis, N-
dc.date.accessioned2017-08-18T00:41:38Z-
dc.date.available2017-08-18T00:41:38Z-
dc.date.issued2017-08-
dc.identifier.citationAsia-Pacific Journal of Clinical Oncology 2017; 13 (Supp 3): 3-13en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/16806-
dc.description.abstractSince the identification of anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) in 2005, the treatment of ALK-rearranged NSCLC (ALK+ NSCLC) has evolved at a rapid pace. This molecularly distinct subset of NSCLC has uniquely important biology, clinicopathologic features and mechanisms of drug resistance which impact on the choice of treatment for a patient with this disease. There are multiple ALK tyrosine kinase inhibitors now available in clinical practice with efficacy data continuing to emerge and guide the optimal treatment algorithm. A detailed search of medical databases and clinical trial registries was conducted to capture all relevant articles on this topic enabling an updated detailed overview of the landscape of management of ALK-rearranged NSCLC.en_US
dc.subjectALKen_US
dc.subjectNon-small cell lung canceren_US
dc.subjectResistanceen_US
dc.subjectSurvivalen_US
dc.subjectTyrosine kinase inhibitorsen_US
dc.titleTreatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian contexten_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleAsia-Pacific Journal of Clinical Oncologyen_US
dc.identifier.affiliationBill Walsh Translational Research Laboratory, Kolling Institute Medical Institute of Research, Royal North Shore Hospital, St Leonards, New South Wales, Australiaen_US
dc.identifier.affiliationSydney Medical School, Northern Clinical School, University of Sydney, Sydney, New South Wales, Australiaen_US
dc.identifier.affiliationNorthern Cancer Institute, St Leonards, New South Wales, Australiaen_US
dc.identifier.affiliationMedical Oncology Unit, Olivia Newton John Cancer and Wellness Centre, Austin Health, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen_US
dc.identifier.affiliationDepartment of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationCancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, New South Wales, Australiaen_US
dc.identifier.affiliationDepartment of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australiaen_US
dc.identifier.affiliationSchool of Medicine, Western Sydney University, Sydney, New South Wales, Australiaen_US
dc.identifier.affiliationSchool of Medicine, University of Western Australia, Perth, Western Australia, Australiaen_US
dc.identifier.affiliationDepartment of Medical Oncology, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australiaen_US
dc.identifier.affiliationLinear Clinical Research, Nedlands, Western Australia, Australiaen_US
dc.identifier.affiliationDepartment of Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australiaen_US
dc.identifier.affiliationDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australiaen_US
dc.identifier.affiliationSir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australiaen_US
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/28795492en_US
dc.identifier.doi10.1111/ajco.12754en_US
dc.type.contentTexten_US
dc.type.austinJournal Articleen_US
local.name.researcherChia, Puey Ling
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

18
checked on Nov 26, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.